Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-center, Open-label, Single-arm, 3+3 Dose-escalation Phase I Clinical Study to Evaluate Safety and Tolerability of HMM910(Human Mesenchymal Stem Cells Injection) in Postmenopausal Women With Osteoporosis and at High Risk of Fracture

NCT06949137 is registered in ClinicalTrials.gov with HELP Therapeutics Co., Ltd. as lead sponsor.

NCT NCT06949137
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06949137 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-center, Open-label, Single-arm, 3+3 Dose-escalation Phase I Clinical Study to Evaluate Safety and Tolerability of HMM910(Human Mesenchymal Stem Cells Injection) in Postmenopausal Women With Osteoporosis and at High Risk of Fracture
Lead sponsor
HELP Therapeutics Co., Ltd.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
June 20, 2025
Completion date
September 6, 2026
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

osteoporosis, osteoporosis in post-menopausal women